Loading...

XOMA XOMA ROYALTY CORP Product Launches 8-K Filing

XM R

XM

XOMA ROYALTY CORP

(XOMA)

2023 8-K

Summary

Summary

Stock Sales Agreement

Correction Filing

Merger Completion

Merger Completed

Financial Results Report

Change of Jurisdiction

Financial Statements

Financial Results

Acquisition Update

Merger Announcement

Q3 Financial Results

Royalty Purchase

Q2 2024 Results

Acquisition of Kinnate Biop...

Sale of Priority Review Vou...

Annual Meeting of Stockholders

Financial Results Announcement

Completion of Acquisition

Merger Agreement

Appointment of CEO

Loan Agreement with Blue Ow...

Financial Results Announcement

Termination of License Agre...

Payment Received

Financial Results Announcement

Product Discontinuation

Acquisition of Assets and R...

Annual Meeting Approval

Financial Results Announcement

Acquisitions and mergers

Financial Results Announcement

Appointment of Owen Hughes ...

External Links:

On July 18, 2023, Novartis International Pharmaceutical Ltd. announced that it is discontinuing its Phase 3 trial for NIS793, an anti-TGFb monoclonal antibody, in first-line metastatic pancreatic ductal adenocarcinoma which was licensed by XOMA Corporation.

AI Assistant

XOMA ROYALTY CORP

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.